Literature DB >> 33910002

Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma.

Bethany Veo1, Etienne Danis1, Angela Pierce2, Dong Wang1, Susan Fosmire1, Kelly D Sullivan3, Molishree Joshi3, Santosh Khanal3, Nathan Dahl2, Sana Karam4, Natalie Serkova5, Sujatha Venkataraman2, Rajeev Vibhakar6.   

Abstract

MYC-driven medulloblastoma is a major therapeutic challenge due to frequent metastasis and a poor 5-year survival rate. MYC gene amplification results in transcriptional dysregulation, proliferation, and survival of malignant cells. To identify therapeutic targets in MYC-amplified medulloblastoma, we employ a CRISPR-Cas9 essentiality screen targeting 1,140 genes. We identify CDK7 as a mediator of medulloblastoma tumorigenesis. Using chemical inhibitors and genetic depletion, we observe cessation of tumor growth in xenograft mouse models and increases in apoptosis. The results are attributed to repression of a core set of MYC-driven transcriptional programs mediating DNA repair. CDK7 inhibition alters RNA polymerase II (RNA Pol II) and MYC association at DNA repair genes. Blocking CDK7 activity sensitizes cells to ionizing radiation leading to accrual of DNA damage, extending survival and tumor latency in xenograft mouse models. Our studies establish the selective inhibition of MYC-driven medulloblastoma by CDK7 inhibition combined with radiation as a viable therapeutic strategy.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enter keywords here

Mesh:

Substances:

Year:  2021        PMID: 33910002     DOI: 10.1016/j.celrep.2021.109013

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  8 in total

Review 1.  Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer.

Authors:  Shreyasi Maity; Rishyani Mukherjee; Satarupa Banerjee
Journal:  Mol Biotechnol       Date:  2022-08-23       Impact factor: 2.860

2.  Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.

Authors:  Meng Li; Yujie Han; Chaochen Wang; Wenfeng Kang; Wenyan Jiang; Lei Zhang; Yujie Tang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-22

3.  A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.

Authors:  Dong Wang; Bethany Veo; Angela Pierce; Susan Fosmire; Krishna Madhavan; Ilango Balakrishnan; Andrew Donson; Irina Alimova; Kelly D Sullivan; Molishree Joshi; Mark Erlander; Maya Ridinger; Nicholas K Foreman; Sujatha Venkataraman; Rajeev Vibhakar
Journal:  Neuro Oncol       Date:  2022-03-12       Impact factor: 13.029

4.  RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.

Authors:  Andrea M Pesch; Nicole H Hirsh; Anna R Michmerhuizen; Kassidy M Jungles; Kari Wilder-Romans; Benjamin C Chandler; Meilan Liu; Lynn M Lerner; Charles A Nino; Connor Ward; Erin F Cobain; Theodore S Lawrence; Lori J Pierce; James M Rae; Corey W Speers
Journal:  JCI Insight       Date:  2022-02-08

5.  SMYD3 Promotes Cell Cycle Progression by Inducing Cyclin D3 Transcription and Stabilizing the Cyclin D1 Protein in Medulloblastoma.

Authors:  Swapna Asuthkar; Sujatha Venkataraman; Janardhan Avilala; Katherine Shishido; Rajeev Vibhakar; Bethany Veo; Ian J Purvis; Maheedhara R Guda; Kiran K Velpula
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer.

Authors:  Siyuan Zeng; Bin Lan; Robert Grützmann; Christian Pilarsky; Xiaofan Ren; Shuman Zhang; Daniel Schreyer; Markus Eckstein; Hai Yang; Nathalie Britzen-Laurent; Andreas Dahl; Debabrata Mukhopadhyay; David Chang; Isabella Kutschick; Susanne Pfeffer; Peter Bailey; Andrew Biankin
Journal:  J Exp Clin Cancer Res       Date:  2022-08-10

7.  Therapeutic Targeting of MYC in Head and Neck Squamous Cell Carcinoma.

Authors:  Shuo Liu; Zhen Qin; Yaqing Mao; Wenbo Zhang; Yujia Wang; Lingfei Jia; Xin Peng
Journal:  Oncoimmunology       Date:  2022-09-30       Impact factor: 7.723

8.  The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells-A Systematic Analysis.

Authors:  Nina Schoenwaelder; Inken Salewski; Nadja Engel; Mareike Krause; Björn Schneider; Michael Müller; Christin Riess; Heiko Lemcke; Anna Skorska; Christina Grosse-Thie; Christian Junghanss; Claudia Maletzki
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.